Johnson Anne Nagengast 4
4 · ATAI Life Sciences N.V. · Filed Mar 15, 2024
Insider Transaction Report
Form 4
Johnson Anne Nagengast
Chief Financial Officer
Transactions
- Award
Stock Option
2024-03-13+550,000→ 550,000 totalExercise: $1.84Exp: 2034-03-13→ Common Shares (550,000 underlying) - Exercise/Conversion
Common Shares
2024-03-14+100,000→ 101,000 total - Exercise/Conversion
Restricted Stock Units
2024-03-14−100,000→ 100,000 total→ Common Shares (100,000 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.
- [F2]The stock option shall vest as to 25% of the underlying shares on January 1, 2025, and in 36 substantially equal monthly installments thereafter.